The CagriSema study results are a setback for the Danish drugmaker in its efforts to regain ground lost to Eli Lilly in the obesity-drug market.
Source link
Novo Nordisk Shares Plunge After Obesity Drug Fails to Beat Zepbound
Date:
More like thisRelated
Is Megan Moroney Dating Christian Pulisic? What We Know
Megan Moroney may have just given the world a...
Crown Holdings Reports Higher Profit as Can Volumes Offset Rising Costs
The company reported a profit of $225 million and...
France’s leaders vow to restore order after weekend of violent riots across the country
Paris — French officials implemented...